Rubinoboletus ballouii polysaccharides exhibited immunostimulatory activities through toll‐like receptor‐4 via NF‐κB pathway

Long‐Fei Li,Grace G.‐L. Yue,Ben C.‐L. Chan,Qiang Zeng,Quan‐Bin Han,Ping‐Chung Leung,Kwok‐Pui Fung,Ji‐Kai Liu,Clara B.‐S. Lau
DOI: https://doi.org/10.1002/ptr.6958
IF: 6.388
2020-11-18
Phytotherapy Research
Abstract:<p>The biological activities of water‐soluble components of edible mushroom <i>Rubinoboletus ballouii</i> (RB) were seldom reported. Polysaccharides of RB (RBP) were prepared and well‐characterized using chemical analyses. The immunomodulatory properties of RBP were investigated using human monocyte‐derived dendritic cells (moDC) <i>in vitro</i>, and cyclophosphamide (CTX)‐induced immunosuppressive mouse model. Results showed that RBP was found to contain 80.6% (w/w) of neutral sugars including <span class="smallCaps">D</span>‐fucose, <span class="smallCaps">D</span>‐mannose, <span class="smallCaps">D</span>‐glucose and <span class="smallCaps">D</span>‐galactose (1.7:1.4:1.0:1.8), and 12.5% (w/w) of proteins, which composed of glutamine, threonine, serine, etc. RBP could promote the maturation of moDC and increase the secretion of IL‐12p40, IL‐10, and TNF‐α. Furthermore, the stimulation of IL‐12p40 production was inhibited by pretreatment with toll‐like receptor (TLR)‐4 blocker or NF‐κB pathway blocker, suggesting that the activation of moDC by RBP was mediated through NF‐κB pathway via TLR‐4 receptor. On the other hand, in CTX‐treated mice, RBP restored the loss of CD34<sup>bright</sup>CD45<sup>dim</sup> hematopoietic stem cells and increased IL‐2 production in sera and splenocytes culture supernatant, as well as up‐regulated the percentage of CD4<sup>+</sup> T helper lymphocyte in mice splenocytes. These findings strongly suggested that RBP are the active ingredients of RB responsible for its immunostimulatory actions and deserved to be further investigated as cancer supplements.</p>
pharmacology & pharmacy,chemistry, medicinal
What problem does this paper attempt to address?
This paper aims to investigate the immunostimulatory activity and mechanism of action of Rubinoboletus ballouii (RB) polysaccharides (RBP). Specifically, the paper explores the role of RBP in immune regulation through in vitro experiments and in vivo models, and verifies whether it promotes the maturation and functional enhancement of immune cells via the Toll-like receptor 4 (TLR-4) mediated NF-κB signaling pathway. ### Main Research Content: 1. **Chemical Characterization**: The composition of RBP was determined through chemical analysis, revealing that it is mainly composed of neutral sugars (such as fucose, mannose, glucose, and galactose) and proteins. 2. **In Vitro Immunostimulatory Activity**: The effects of RBP on human peripheral blood mononuclear cells (PBMC) and monocyte-derived dendritic cells (moDC) were studied. The results showed that RBP significantly increased the secretion of pro-inflammatory cytokines (such as TNF-α and IL-1β), but had no significant effect on T lymphocyte-related cytokines (such as IL-2 and IL-4). 3. **TLR-4/NF-κB Signaling Pathway**: Further studies indicated that RBP promotes the maturation of moDC through the TLR-4 mediated NF-κB pathway, while other signaling pathways (such as PI3K, ERK, etc.) were not significantly involved in this process. 4. **In Vivo Experiments**: Using a cyclophosphamide (CTX)-induced immunosuppressive mouse model, it was found that RBP could restore bone marrow hematopoietic function and partially reverse the inhibitory effects of CTX on T lymphocyte subsets (such as CD4+ T cells). 5. **IL-2 Production**: RBP also increased the levels of IL-2 in the serum and spleen cell culture supernatants of CTX-treated mice, indicating its potential immunomodulatory effects. In summary, this paper reveals that RB polysaccharides, as a potential immunomodulator, exhibit significant immunostimulatory activity both in vitro and in vivo, and elaborates on its possible mechanism of action. These findings provide a theoretical basis for further development of RBP as an adjuvant therapy for cancer.